Skip to main content
. Author manuscript; available in PMC: 2016 May 15.
Published in final edited form as: Clin Cancer Res. 2015 Feb 23;21(10):2338–2347. doi: 10.1158/1078-0432.CCR-14-3000

Figure 4. Targeting MUC1-C with GO-203/NPs is effective against NSCLC cells.

Figure 4

A. H1975 (left) and H460 (right) cells were treated with 7.5 µM GO-203/NPs or an equal amount of empty NPs on day 0. The results are expressed as percent cell death (mean±SD of three replicates) on day 3. B. H1975 cells were left untreated (Control) or treated with 7.5 µM GO-203/NPs once on day 0 and cultured for 3 days (left). Whole cell lysates were separated in non-reducing gels and analyzed by immunoblotting with the indicated antibodies. H1975 cells were treated with 7.5 µM GO-203/NPs, 7.5 µM CP-2/NPs or an equal amount of empty NPs once on day 0 (right). GO-203/NP treated cells were also incubated in the presence of 2.5 mM NAC. Lysates obtained on day 2 were immunoblotted with the indicated antibodies. C. H1975 cells were left untreated (Control) or treated with 15 µM GO-203/NPs or CP-2/NPs once on day 0. Cells were analyzed on day 2 for relative NADPH (left) and GSH (right) levels (mean±SD of three replicates) as compared to that obtained for the control. D. H1975 cells were left untreated (Control) or treated with 15 µM GO-203/NPs or CP-2/NPs for 24 h. GO-203/NP treated cells were also incubated in the presence of 2.5 mM NAC for 24 h. Lysates were immunoblotted with the indicated antibodies.

HHS Vulnerability Disclosure